Enhancing immune responses against neuroblastoma by targeting Syk
Targeting Syk to enhance anti-tumor immune responses in neuroblastoma
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN DIEGO · NIH-11078225
This study is looking at how a protein called Syk helps neuroblastoma, a type of cancer in kids, hide from the immune system, and it will test if using Syk blockers along with current treatments can help the body fight the cancer better.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN DIEGO (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-11078225 on ClinicalTrials.gov |
What this research studies
This research focuses on improving treatments for neuroblastoma, a common pediatric cancer, by investigating how a specific protein called Syk contributes to the tumor's ability to suppress the immune system. The study aims to understand the mechanisms by which tumor-associated macrophages inhibit immune responses and to test whether using Syk inhibitors alongside existing therapies can enhance the body's ability to fight the cancer. By utilizing mouse models, the researchers will explore the effectiveness of these combined treatments in overcoming resistance to current immunotherapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with high-risk neuroblastoma.
Not a fit: Patients with neuroblastoma who are not classified as high-risk or those outside the age range of 0-11 years may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for children with neuroblastoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other cancers, suggesting that this approach may yield beneficial results in neuroblastoma as well.
Where this research is happening
LA JOLLA, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN DIEGO — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JOSHI, SHWETA — UNIVERSITY OF CALIFORNIA, SAN DIEGO
- Study coordinator: JOSHI, SHWETA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.